«Results demonstrate that ECIS can potentially be used to screen for
osteogenic potential of hASC, track the stages of
osteogenic differentiation for quality control purposes and better explain the underlying biological causes of variability among donors — and since the results typically are
in «real - time,» this technology could be incorporated into future manufacturing to track hASC throughout the process.»
The cells (Photo 5) can be delivered
in a number of carrier systems designed to retain the cells at the site of interest, to make delivery through a percutaneous approach easy and safe and to augment the
osteogenic potential of the cells.